Latest Conference Articles

Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.

International investigators observe differing levels of severe COVID-19 risk for patients with atopic dermatitis, dependent on their current therapy.

Data from the phase 3 TRuE-V clinical program show the topical JAK inhibitor provided substantial repigmentation to more than half of treated patients.

Data from a pair of phase 3 trials concluded that oral baricitinib was superior to placebo for patients with severe alopecia areata for hair regrowth at 36 weeks.

A Perelman School of Medicine assessment of biopsy rates support previous findings showing that dermatologists are less confident making psoriasis diagnoses in patients with darker skin color.

John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.

New data suggest that treatment with dupilumab does not increase the risk of COVID-19 infection in patients with atopic diseases.

John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.

The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.

New AAD 2022 pooled analysis show the PDE-4 inhibitor topical therapy provides tolerable and effective improvement at 8 weeks.

Those who are underweight or normal weight were more likely to have an IgE mediated food allergy.

Gestational age and NICU admission both were associated with the risk of developing EoE.

The reductions were seen as early as week 2 and was sustained throughout the 52 week study.

The algorithm also resulted in a large reduction in oral food challenges.

Additionally, the association between atopic dermatitis and sensitization to eggs was more common during the pandemic then in years prior.

By blocking certain neurogenic changes that occur in the lungs at childhood, patients may avoid asthma and allergic responses into adulthood.

Investigators examined data on abrocitinib from the JADE REGIMEN study.

Currently, antibiotics comprise roughly 80% of prescribed pregnancy medications, and recent epidemiological studies have indicated a link between antibiotic use and dysbiosis.

Dr. Mathias noted that investigators are continuing to determine if age plays a role in peanut allergy risk and sensitization.

Itch intensity was highest at bedtime compared to all other time periods of the day.

This decision could further exacerbate health inequities among populations that are socioeconomically disadvantaged.

The study found that PARTICS, in addition to the usual care these patients received, reduced severe asthma exacerbations by 15.4% (p50.048) which corresponded to a reduction of 13 exacerbations/100 patient-years.

Patients with allergic asthma could often have no clinical history of atopic dermatitis.

Most cases had onset after 4 hours and were mild, which Dr. Anvari noted should not contraindicate future COVID-19 vaccine doses.

To date, dupilumab is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents with EoE.

Knowledge on distinguishing moderate and severe eczema increased the most after the video training.

Investigators from the Cincinnati Children’s Hospital Medical Center tested a new allergic reaction severity grading system.

Dr. McKeon speaks of how patients can be more involved with managing their asthma and allergies by avoiding exposures in their own homes.

The most common burden of disease were itching, dry or rough skin, and cracked skin.

Those who were breastfed for less than 4 months also had lower risks of developing atopic diseases.